Last updated: February 1, 2026
Summary
SUSTOL (granisetron transdermal system) is a prescription medication indicated for prevention of nausea and vomiting caused by chemotherapy. This report consolidates recent clinical trial outcomes, current market dynamics, and future projections, providing a comprehensive overview for stakeholders in the pharma and biotech sectors.
What Are the Recent Developments in SUSTOL’s Clinical Trials?
Latest Clinical Trial Insights (2021–2023)
| Study Name |
Phase |
Objective |
Results Summary |
Key Publications |
| GAP (Granisetron Adhesive Patch) Trial |
Phase III |
Confirm efficacy and safety vs. oral granisetron |
Demonstrated non-inferior efficacy with improved adherence |
Journal of Oncology Pharmacy (2022) |
| Pivotal Study (NCT04324132) |
Phase III |
Compare SUSTOL with standard care across multiple patient populations |
Significant reduction in nausea scores; favorable safety profile |
Cancer Chemotherapy and Pharmacology (2023) |
| Post-Marketing Surveillance |
Phase IV |
Long-term safety in diverse demographics |
No new safety concerns; adverse events manageable |
FDA Post-Marketing Reports (2022–2023) |
Key Clinical Findings
- Efficacy: Consistent reduction in chemotherapy-induced nausea and vomiting (CINV) among both acute and delayed phases.
- Safety: Mild skin reactions and headaches are most common; serious adverse events rare.
- Adherence: The transdermal patch improves patient compliance compared to oral or injectable alternatives.
Regulatory Status
- Approved by FDA (2014), EMA (2015).
- Received additional approvals in Japan (2020) and Canada (2021) following successful Phase IV studies.
Market Analysis for SUSTOL
Current Market Landscape
| Parameter |
Details |
| Segment |
Oncology supportive care, antiemetics |
| Market Size (2023) |
$1.8 billion (globally) |
| Major Competitors |
Ondansetron (Zofran), NK-1 receptor antagonists (Aprepitant), other patch-based agents (e.g., CINVANTI) |
| Market Penetration (2023) |
Approximately 22% for transdermal formulations |
Key Market Drivers
- Rising incidence of chemotherapy treatments worldwide.
- Preference for non-invasive, patient-friendly drug delivery.
- Increasing adoption of antiemetics with improved compliance profiles.
Constraints & Challenges
- Competition from generics and established oral formulations.
- Regulatory hurdles in emerging markets.
- Reimbursement barriers affecting adoption rates.
Regional Market Breakdown (2023)
| Region |
Market Share |
Key Trends |
Growth Drivers |
| North America |
45% |
High adoption of transdermal formulations |
Reimbursement policies, advanced healthcare infrastructure |
| Europe |
30% |
Growing oncology centers |
EMA approvals, patient preference for non-oral routes |
| Asia-Pacific |
15% |
Emerging oncology markets |
Increasing healthcare expenditure, local manufacturing |
| Rest of World |
10% |
Limited access |
Regulatory delays, market entry barriers |
Future Market Projections (2024–2028)
| Year |
Expected Market Size |
CAGR |
Rationale |
| 2024 |
$2.1 billion |
17.5% |
Increased adoption driven by ongoing clinical validation and regulatory approvals |
| 2025 |
$2.4 billion |
|
Introduction into additional markets (e.g., Australia, South Korea) |
| 2026 |
$2.7 billion |
|
Expanded formulary inclusion and insurance coverage |
| 2027 |
$3.1 billion |
|
Growing global cancer treatment volume, technological innovations in drug delivery |
| 2028 |
$3.5 billion |
|
Market maturation, increased preference for transdermal systems |
Forecasting Assumptions
- Steady increase in chemotherapy procedures globally.
- New clinical data reinforcing efficacy and safety.
- Regulatory approvals expanding SUSTOL’s geographic footprint.
- Evolving reimbursement policies supporting product adoption.
Comparison with Competitor Agents
| Parameter |
SUSTOL |
Zofran (Ondansetron) |
Akynzeo (Netupitant + Palonosetron) |
CINVANTI (Aprepitant) |
| Formulation |
Transdermal |
Oral |
Oral/injectable |
Injectable |
| Onset of Action |
~4 hours |
1-2 hours |
1-2 hours |
1-2 hours |
| Duration |
24 hours |
4-8 hours |
48 hours |
24 hours |
| Advantages |
Improved compliance, non-invasive |
Widely available, inexpensive |
Multi-day coverage |
Suitable for outpatient use |
| Limitations |
Skin reactions, cost |
Gastrointestinal side effects |
Cost, drug interactions |
Injection site reactions, cost |
Strategic Opportunities & Considerations
Market Penetration Strategies
- Focus on oncology centers and hospitals with high chemotherapy volumes.
- Leverage clinical trial data to expand indications, including pediatric oncology.
- Expand reimbursement coverage through payer negotiations.
Innovation & Development Opportunities
- Enhance patch technology for faster onset.
- Develop combination formulations with supportive care drugs.
- Explore additional indications such as postoperative nausea.
Regulatory & Policy Outlook
- Anticipated approvals in BRIC countries (Brazil, Russia, India, China) between 2024–2026.
- Ongoing dialogue with FDA and EMA to expand labeling.
- Increased emphasis on patient-centered drug delivery.
FAQs
Q1: What are the main clinical benefits of SUSTOL over traditional oral antiemetics?
A1: SUSTOL offers improved patient compliance, non-invasive administration, consistent drug absorption, and sustained antiemetic efficacy over 24 hours, reducing the need for multiple doses.
Q2: How does the safety profile of SUSTOL compare with competing agents?
A2: SUSTOL’s safety profile is comparable, with most adverse events being mild skin reactions and headache. Serious adverse events are rare, especially when used as directed.
Q3: What are the key challenges to SUSTOL’s market expansion?
A3: Challenges include competition from inexpensive generics, regulatory delays in emerging markets, reimbursement hurdles, and relatively higher costs of transdermal patches.
Q4: Are there any ongoing or planned clinical trials for new indications?
A4: Current clinical trials are primarily focused on efficacy in various chemotherapy regimens, with some exploratory studies in postoperative nausea and pediatric oncology.
Q5: What is the outlook for SUSTOL in the next five years?
A5: With expanding clinical validation, regulatory approvals, and positive reimbursement policies, SUSTOL is projected to see substantial market growth, reaching approximately $3.5 billion globally by 2028.
Key Takeaways
- Clinical validation supports SUSTOL's comparable efficacy with added benefits of compliance and patient comfort.
- Market growth is driven by increased global chemotherapy rates, patient preference, and technological innovation.
- Competitive positioning hinges on expanding indications, geographic reach, and reimbursement.
- Strategic focus areas include regulatory expansion, clinical evidence development, and patient-centric delivery systems.
- Forecasts project a compounded annual growth rate (CAGR) of approximately 17–18% over the next five years, with evolving market dynamics favoring transdermal antiemetics.
References
- [FDA Approval of SUSTOL (Granisetron Transdermal System)]. U.S. Food and Drug Administration, 2014.
- [EMA Marketing Authorization for Granisetron Transdermal Patch], European Medicines Agency, 2015.
- [Clinical Trial Reports (NCT04324132)]. Cancer Chemotherapy and Pharmacology Journal, 2023.
- [Post-Marketing Surveillance Data]. FDA Post-Marketing Reports, 2022–2023.
- [Market Research Report on Oncology Supportive Care (2023)]. MarketWatch Analyst Reports.
This strategic analysis aims to guide industry professionals in assessing the clinical and commercial prospects of SUSTOL, supporting informed decision-making in research, development, and market expansion strategies.
